JPRN-UMIN000022222Completed未知
The efficacy of ferulic acid in the treatment of dementia (double-blinded study) - EFATD2
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Shimane University
- Enrollment
- 100
Study Overview
Brief Summary
This trial was done for mild cognitive impairment(MCI). There were not significant difference in MMSE, HDS-R, FAB(frontal assessment battery),hippocampal atrophy (MRI VSRAD) and ADAS-cog between ferulic acid group(n=37) and placebo group(n=41) for one year.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 65years-old to 89years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •metabolic encephalopathy(hypothyroidism),head trauma,malignancy,alcohl abuse, mental disorder,chronic renal failure, chronic heart failure,chronic liver injury and patients treated by major tranquilizer.
Investigators
Similar Trials
Completed
Not Applicable
The efficacy of ferulic acid in the treatment of dementiaJPRN-UMIN000003683Shimane University Hospital50
Completed
Phase 3
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney DiseaseRenal Insufficiency, ChronicIron-Deficiency AnemiaNCT02968368Shield Therapeutics167
Unknown
Phase 2
Folinic Acid in Children With Autism Spectrum DisordersAutism Spectrum DisorderNCT02551380Central Hospital, Nancy, France40
Completed
Phase 3
EFFICACY OF RUESI DADTON ON MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROL TRIAmild cognitive impairmentelderlymild cognitive impairmentelderlyThai exerciseRuesi DadtonBDNFirisinoxidative stressmind body medicineTCTR20200727001-71
Completed
Phase 3
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBDAnemia, Iron-DeficiencyCrohn's DiseaseInflammatory Bowel DiseaseNCT02680756Shield Therapeutics250